scispace - formally typeset
Open AccessJournal ArticleDOI

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.

Merryn Voysey, +766 more
- 06 Mar 2021 - 
- Vol. 397, Iss: 10277, pp 881-891
TLDR
The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given with an interval of 4-12 weeks as discussed by the authors.
About
This article is published in The Lancet.The article was published on 2021-03-06 and is currently open access. It has received 862 citations till now. The article focuses on the topics: Booster dose & Vaccine efficacy.

read more

Citations
More filters
Journal ArticleDOI

Safety and immunogenicity of heterologous ChAdOx1-nCoV19 and BNT162b2 vaccination: A meta-analysis of the heterologous COVID-19 vaccination outcomes

TL;DR: In this paper , the safety and immunogenicity of the heterologous ChAd/BNT vaccination regimens were evaluated using the pooled risk ratios (RRs) calculated by the random-effects model about the adverse events.
Book ChapterDOI

Treatment Approach, Pharmacological Agents and Vaccines

TL;DR: This chapter gives an overview of the medical treatment approach for the hospitalized patient and the various neurological complications associated with each of the treatments in use in the United States and goes over vaccines’ neurological side effects and special considerations for patients with different neurological conditions.
Posted ContentDOI

Immunogenicity and Protective Efficacy of a SARS-CoV-2 mRNA Vaccine Encoding Secreted Non-Stabilized Spike Protein in Mice

TL;DR: ChulaCov19 as mentioned in this paper encapsulates prefusion-unstabilized ectodomain spike protein encapsulated in lipid nanoparticles (LNP) for SARS-CoV-2 viremia.
Journal ArticleDOI

Tuberculosis and hepatitis C virus coinfection in a renal transplant recipient: A therapeutic challenge

TL;DR: Nabulsi et al. as discussed by the authors reported a case where co-administration of antitubercular treatment (ATT) along with sofosbuvir/velpatasvir, resulted in failure of DAA regimen.
Book ChapterDOI

Viral Infections

References
More filters
Journal ArticleDOI

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

Merryn Voysey, +81 more
- 09 Jan 2021 - 
TL;DR: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials.
Journal ArticleDOI

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.

TL;DR: The specific objectives of this report were to assess the safety and humoral and cellular immunogenicity of a single-dose and two-dose schedule in adults older than 55 years, and safety, as measured by the occurrence of serious adverse events.
Related Papers (5)

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

Merryn Voysey, +81 more
- 09 Jan 2021 -